BCAL Diagnostics (ASX:BDX) Scaled Net Operating Assets : 0.30 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is BCAL Diagnostics Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

BCAL Diagnostics's operating assets for the quarter that ended in Dec. 2023 was A$3.41 Mil. BCAL Diagnostics's operating liabilities for the quarter that ended in Dec. 2023 was A$0.85 Mil. BCAL Diagnostics's Total Assets for the quarter that ended in Jun. 2023 was A$8.37 Mil. Therefore, BCAL Diagnostics's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2023 was 0.30.

BCAL Diagnostics Scaled Net Operating Assets Historical Data

The historical data trend for BCAL Diagnostics's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BCAL Diagnostics Scaled Net Operating Assets Chart

BCAL Diagnostics Annual Data

Trend

Jun22

Jun23

Scaled Net Operating Assets

0.01

0.29

BCAL Diagnostics Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Scaled Net Operating Assets	Get a 7-Day Free Trial			0.02	0.01	0.07	0.39	0.31

Competitive Comparison of BCAL Diagnostics's Scaled Net Operating Assets

For the Diagnostics & Research subindustry, BCAL Diagnostics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BCAL Diagnostics's Scaled Net Operating Assets Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, BCAL Diagnostics's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where BCAL Diagnostics's Scaled Net Operating Assets falls into.

BCAL Diagnostics Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

BCAL Diagnostics's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Jun. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Jun. 2023 )
=	(Operating Assets (A: Jun. 2023 )	-	Operating Liabilities (A: Jun. 2023 ))	/	Total Assets (A: Jun. 2022 )
=	(5.197	-	2.095)	/	10.59
=	0.29

where

	Operating Assets		(A: Jun. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	8.371	-	3.174
=	5.197

	Operating Liabilities		(A: Jun. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	3.157	-	0.897	-	0.165
=	2.095

BCAL Diagnostics's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Dec. 2023 )
=	(Operating Assets (Q: Dec. 2023 )	-	Operating Liabilities (Q: Dec. 2023 ))	/	Total Assets (Q: Jun. 2023 )
=	(3.405	-	0.852)	/	8.371
=	0.30

where

	Operating Assets		(Q: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	8.422	-	5.017
=	3.405

	Operating Liabilities		(Q: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	2.355	-	1.139	-	0.364
=	0.852

BCAL Diagnostics Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of BCAL Diagnostics's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

BCAL Diagnostics (ASX:BDX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BCAL Diagnostics Ltd (ASX:BDX) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

Queen Victoria Building, GPO Box Q128, Sydney, NSW, AUS, 1230

Website

https://www.bcaldiagnostics.com

BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer by identifying, measuring, and validating specific biomarkers enriched from patient's blood. The BCAL technology utilizes a single blood test on multiple levels including disease detection, diagnostic mass screening, and post-intervention.